FFC#2/2021

Harnessing CRISPR-Cas technology to revert F508del and 2789+5G>A CFTR defects

AREA 1 Therapies to correct the underlying defect

FFC#2/2021

Harnessing CRISPR-Cas technology to revert F508del and 2789+5G>A CFTR defects
€ 0 still needed
0%
€ 103.450 goal

pRINCIPAL INVESTIGATOR

Anna Cereseto (Università di Trento)

Partner

Daniele Arosio (Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Trento)

Researchers

6

Category

AREA 1 Therapies to correct the underlying defect

Duration

2 years

Goal

€ 103.450

Funds raised

€ 103.450

Objectives

This project, an extension of the previous FFC#3/2019 and proposed by the same research group, aims to use gene editing to restore the function of the CFTR gene by exploiting the neutralizing mutations (capable of neutralizing the effect of the original mutation causing the disease). The splicing mutation 2789+5G>A, one of the 20 most frequent mutations among the 360 identified as a cause of cystic fibrosis (CF), will be repaired through the strategy used in the previous project (FFC#3/2019) and exploiting the new base editing technologies, able to modify the single nucleotide in a targeted way. The therapeutic modifications will be inserted through CRISPR-Cas in cellular models of cystic fibrosis such as bronchial epithelial cells and intestinal organoids derived from person with CF with F508del or 2789 + 5G> A mutations.

XIX Convention FFC Ricerca – download here a brief presentation of the project

WHO ADOPTED THE PROJECT

“Together for Life” 2021

€ 103.450

Gruppo di sostegno FFC Ricerca Genova “Mamme per la ricerca”

€ 50.000

Delegazione FFC Ricerca di Prato

€ 15.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches